Literature DB >> 2649356

A rational approach to the prevention and treatment of postmenopausal osteoporosis.

T D Spector1, E C Huskisson.   

Abstract

Postmenopausal osteoporosis is a common disorder. Its importance is measured by the mortality and morbidity associated with increasing numbers of fractures and the enormous social and economic cost to the community. Although the precise aetiology of postmenopausal osteoporosis remains unclear, prevention is now possible and treatment may be effective if commenced early enough in the course of the disease. Combination therapy with oestrogens and progestogens is currently the treatment of choice for prevention, in conjunction with calcium supplementation and changes in lifestyle. Prophylaxis should be offered to women at 'high risk', although the identification of this group is difficult at present. Treatment of existing disease is less effective, although oestrogens should be tried first, with calcitonin as a second choice. There is no place at present for vitamin D, anabolic steroids or parathyroid hormone. The use of fluoride or diphosphonates cannot be recommended outside research centres until further long term studies are completed, which will enable a comparison of the relative risks and benefits. Postmenopausal osteoporosis is now a preventable disease; however, further knowledge of risk factors and the identification of those at risk is essential. Treatment can then be directed at women who need it and healthy women can be spared a lifetime of unnecessary medication.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2649356     DOI: 10.2165/00003495-198937020-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  29 in total

Review 1.  Consensus development conference: prophylaxis and treatment of osteoporosis.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-10

2.  Prediction of rapid bone loss in postmenopausal women.

Authors:  C Christiansen; B J Riis; P Rødbro
Journal:  Lancet       Date:  1987-05-16       Impact factor: 79.321

3.  Physical activity and calcium modalities for bone mineral increase in aged women.

Authors:  E L Smith; W Reddan; P E Smith
Journal:  Med Sci Sports Exerc       Date:  1981       Impact factor: 5.411

4.  Post-menopausal and corticosteroid-induced osteoporosis.

Authors:  R G Crilly; A Horsman; D H Marshall; B E Nordin
Journal:  Front Horm Res       Date:  1977       Impact factor: 2.606

Review 5.  Long-term effects of postmenopausal hormone therapy.

Authors:  K Hunt; M Vessey
Journal:  Br J Hosp Med       Date:  1987-11

6.  Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females.

Authors:  C Christiansen; M S Christensen; P McNair; C Hagen; K E Stocklund; I Transbøl
Journal:  Eur J Clin Invest       Date:  1980-08       Impact factor: 4.686

7.  Fracture of neck of the femur: changing incidence.

Authors:  A F Lewis
Journal:  Br Med J (Clin Res Ed)       Date:  1981-11-07

8.  Rising incidence of fracture of the proximal femur.

Authors:  W J Boyce; M P Vessey
Journal:  Lancet       Date:  1985-01-19       Impact factor: 79.321

9.  Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy.

Authors:  B L Riggs; E Seeman; S F Hodgson; D R Taves; W M O'Fallon
Journal:  N Engl J Med       Date:  1982-02-25       Impact factor: 91.245

10.  Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

Authors:  I R Reid; A R King; C J Alexander; H K Ibbertson
Journal:  Lancet       Date:  1988-01-23       Impact factor: 79.321

View more
  2 in total

Review 1.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

Review 2.  Transdermal estradiol. A review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis.

Authors:  J A Balfour; D McTavish
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.